View
20
Download
0
Category
Preview:
DESCRIPTION
China has the world’s largest diabetes epidemic, and it continues to grow at a fearsome pace. The latest research report provides an overview of the china diabates market and examines the aspects of the prevalence, demographical breakup, diagnosis and treatment of diabetes in China. Read full report here: http://www.imarcgroup.com/china-diabetes-market - PowerPoint PPT Presentation
Citation preview
Imarcwww.imarcgroup.com
Consulting Services
Copyright © 2015 International Market Analysis Research & Consulting (IMARC). All Rights Reserved
China Diabetes Market Report: Patients, Prevalence, Oral
Antidiabetics, Insulin and Diagnostics
IMARC Group
Email: sales@imarcgroup.com
Website: www.imarcgroup.com
Phone: (US)+1-631-791-1145,
(IND) 91-120-415-5099
The International Market Analysis Research and Consulting Group is a leading advisor on managementstrategy and market research worldwide. We partner with clients in all sectors and regions to identifytheir highest-value opportunities, address their most critical challenges, and transform theirbusinesses.
IMARC’s information products include major market, scientific, economic and technologicaldevelopments for business leaders in pharmaceutical, industrial, and high technology organizations.Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, foodand beverage, travel and tourism, nanotechnology and novel processing methods are at the top of thecompany’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies andmarkets with close cooperation at all levels of the client organization. This ensures that our clientsachieve unmatchable competitive advantage, build more proficient organizations, and secure lastingresults.
Report DescriptionAbout IMARC GroupImarc
www.imarcgroup.com
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
China Diabetes Market: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics
Driven by a large diabetic population, continuous economic growth and increasing disposable incomes, thediabetes market - Non-Insulin Anti-diabetics, Insulin and Diabetes Diagnostics is witnessing double digitgrowth rates.
As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise toanother sickness - a rapid increase in a life-style disease called diabetes. With the Chinese population gettingricher, fatter and less mobile, there has been a surge in the prevalence of diabetes. With a prevalence rate ofaround 12 percent in the adult population, China currently represents the diabetes capital of the world.
The rising prevalence of diabetes, however, is catalysing the market for diabetes products in the country. Drivenby a continuous economic growth and increasing disposable incomes, the diabetes market - Non-Insulin Anti-diabetics, Insulin and Diabetes Diagnostics is witnessing double digit growth rates and creating lucrativeopportunities for global pharmaceutical and diagnostic companies at a time when growth rates in the moredeveloped markets have declined.
IMARC’s new report “China Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin andDiagnostics” provides an analytical and statistical insight into the Chinese diabetes market. The report providesboth current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetesin China. The research study serves as an exceptional tool to understand the epidemiology, market trends,therapeutic structure, competitive structure and the outlook of the Chinese diabetes market. This report canserve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who areplanning to foray into the Chinese diabetes market in any form.
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
What we have achieved in this report:
Comprehensive situation analysis of the Chinese diabetes epidemiology and its dynamics:
Focus of the Analysis:
• Historical, current and future prevalence of diabetes in China• Historical, current and future prevalence of type-1 and type-2 diabetes in China• Historical, current and future prevalence of diabetes in the urban and rural regions in China• Historical, current and future prevalence of diabetes among males and females in China• Historical, current and future prevalence of diabetes among various age groups in China• Historical, current and future diagnosis rates for diabetes in China• Historical, current and future drug treatment rates for diabetes in China
Comprehensive situation analysis of the Chinese Oral Antidiabetics market and its dynamics:
Focus of the Analysis:
• Performance of the Oral Antidiabetics market in China• Performance of key classes• Performance of key players• Market outlook
Report DescriptionChina Diabetes MarketImarc
www.imarcgroup.com
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
Comprehensive situation analysis of the Chinese Insulin market and its dynamics:
Focus of the Analysis:
• Performance of the Insulin market in China• Performance of key classes• Performance of key players• Market outlook
Comprehensive situation analysis of the Chinese diabetes diagnostics market and its dynamics:
Focus of the Analysis:
• Performance of the diabetes diagnostics market in China• Market segmentation• Key players• Market outlook
Table of Contents
1 Research Methodology2 Executive Summary3 Diabetes Disease Overview3.1 What is Diabetes?
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
3.2 Diabetes Diagnosis and Treatment3.2.1 Diagnosis3.2.2 Treatment3.3 Diabetes Complications4 Key Factors Driving the Diabetes Market in China5 China Diabetes Epidemiology5.1 Diabetes Population and Prevalence Rates5.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)5.3 Population and Prevalence Rates by Region 5.4 Population and Prevalence Rates by Gender5.5 Population and Prevalence Rates by Age Group5.6 Diabetes Diagnosis and Drug Treatment Rates6 China Diabetes Market6.1 Historical Market Trends (2007-2014)6.2 Market Breakup by Segment (2007-2014)6.3 China Oral Antidiabetics Market6.3.1 Historical Market Trends (2007-2014)6.3.2 Market Breakup by Class (2007-2014)6.3.3 Market Shares of Key Players6.3.4 Market Outlook (2015-2020)6.4 China Insulin Market6.4.1 Historical Market Trends (2015-2020)6.4.2 Market Breakup by Class6.4.3 Market Shares of Key Players
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
6.4.4 Market Outlook (2015-2020)6.5 Market Outlook (2015-2020)7 China Diabetes Diagnostics Market7.1 Historical Market Trends (2007-2014)7.2 Market Segmentation7.3 Key Players7.4 Market Outlook (2015-2020)
List of Figures
Figure 3 1: The Impact of Diabetes on the Human BodyFigure 3 2: Diabetes ComplicationsFigure 4 1: China: Overweight & Obese Population (in Millions), 2007, 2014 & 2020Figure 4 2: Body Mass Index and Relative Risk of Type-2 DiabetesFigure 4 3: Global: Breakup of Diabetes Patients by Region (in %), 2014 & 2030Figure 5 1: China: Total Number of Diabetes Patients (in Millions), 2007- 2014Figure 5 2: China: Total Number of Diabetes Patients (in Millions), 2015 – 2020Figure 5 3: China (Type1 & Type2): Total Number of Diabetes Patients (in Millions), 2007- 2014Figure 5 4: China (Type1 & Type2): Total Number of Diabetes Patients (in Millions) 2015 – 2020Figure 5 5: China (Urban & Rural): Total Number of Diabetes Patients (in Millions), 2007- 2014Figure 5 6: China (Urban & Rural): Total Number of Diabetes Patients (in Millions), 2015 – 2020Figure 5 7: China (Male & Female): Total Number of Diabetes Patients (in Millions), 2007- 2014Figure 5 8: China (Male & Female): Total Number of Diabetes Patients (in Millions), 2015 – 2020
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
Figure 5 9: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in Millions), 2007-2014Figure 5 10: China: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in Millions), 2015 – 2020Figure 5 11: China: Total Diagnosed & Drug Treated Diabetes Population (in Millions), 2007- 2014Figure 5 12: China: Total Diagnosed & Drug Treated Diabetes Population (in Millions), 2015 – 2020Figure 6 1: China: Diabetes Market (in Million US$), 2007-2014Figure 6 2: China: Diabetes Market: Share of Oral Antidiabetics and Insulin (in %), 2007-2014Figure 6 3: China: Oral Antidiabetics Market (in Million US$), 2007-2014Figure 6 4: China: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2007-2014Figure 6 5: China: Oral Antidiabetics Market: Sales Share of Key Players (in %)Figure 6 6: China: Oral Antidiabetics Market Forecast (in Million US$), 2015-2020Figure 6 7: China: Oral Antidiabetics Market Forecast: Sales Share of Key Classes (in %), 2015 & 2020Figure 6 8: China: Insulin Market (in Million US$), 2007-2014Figure 6 9: China: Insulin Market: Sales Share of Key Classes (in %), 2014Figure 6 10: China: Insulin Market: Sales Share of Key Players (in %)Figure 6 11: China: Insulin Market Forecast (in Million US$), 2015-2020Figure 6 12: China: Insulin Market Forecast: Sales Share of Key Classes (in %), 2015 & 2020Figure 6 13: China: Diabetes Market Forecast (in Million US$), 2015-2020Figure 6 14: China: Diabetes Market Forecast: Share of Oral Antidiabetics and Insulin (in %), 2015-2020Figure 7 1: China: Diabetes Diagnostics Market (in Million US$), 2007-2014Figure 7 2: China: Diabetes Diagnostics Market Forecast (in Million US$), 2015-2020
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
List of Tables
Table 2 1: China: Diabetes Epidemiology: Executive SummaryTable 2 2: China: Diabetes Market: Executive SummaryTable 3 1: Diagnosis of DiabetesTable 4 1: China: Overweight & Obesity Statistics, 2006, 2010 & 2014Table 4 2: China: Urban & Rural Population Breakup (in Millions), 1991, 2001, 2011 & 2014Table 4 3: Global: Diabetes Population Breakup by Country (in 000’s), 2014 & 2020Table 4 4: Global: Market Size & Growth Rates of Top Emerging and Developed Diabetes Drug MarketsTable 5 1: China: Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020Table 5 2: China (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020Table 5 3: China (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020Table 5 4: China (Male & Female): Total Prevalence & Number of Diabetes Patients, 2007, 2014 & 2020Table 5 5: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2007, 2014 & 2020Table 5 6: China: Total Diagnosed & Drug Treated Diabetes Population, 2007, 2014 & 2020
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia:Email: apac@imarcgroup.comPhone: +91-120-415-5099
IMARC Group North America:Email: america@imarcgroup.comPhone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa:Email:ema@imarcgroup.comPhone: +44-702-409-7331
To know more please visit: http://www.imarcgroup.com/china-diabetes-market
Report DescriptionReport Description and HighlightsImarc
www.imarcgroup.com
© 2015 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name ofInternational Market Analysis Research and Consulting (IMARC). No part of this publication may bereproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not beused in any form or by and means graphic electronic or mechanical, including photocopying, recording,taping or by information storage or retrieval, or by any other form, without the express consent ofInternational Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have beenbased on information and sources believed to be accurate and reliable at the time of publishing.International Market Analysis Research and Consulting makes no representation of warranty of any kind as tothe accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for anyloss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International MarketAnalysis Research and Consulting. All other trademarks used in this publication are registered trademarks oftheir respective companies.
FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +91-120-4155099
E-MAIL: sales@imarcgroup.com
http://www.imarcgroup.com
Contact Us
Recommended